• Skip to main content
  • Skip to secondary menu
  • Skip to footer

ESN.net

event sharing network

  • Share Your Event
    • Make a Contribution
  • Events
  • Job Board
  • Markets
  • About
    • Event Marketing: A Catalyst for Business Success
    • Leveraging Social Media for Event Promotion: A Winning Strategy
    • Targeting the Right Audience: The Key to Successful Event Promotion
    • The Power of Media: Maximizing Event Promotion through the Media
    • Capturing the Moment: The Importance of Photo and Video Coverage in Event Promotion
    • Voices of the Event: The Power of Interviews as a Promotion Tool
    • The Power of Podcasts: Using Audio as a Tool for Event Promotion
    • Bridging the Gap: How Virtual Events Complement Physical Ones and Expand Reach and Audience
    • The Future is Now: How Innovation is Revolutionizing Event Management and Promotion
  • Contact

Rx and Illicit Drug Summit (Rx Summit), April 18-21 in Atlanta, GA

April 18, 2022 By admin Leave a Comment

Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the treatment of substance use and opioid use disorders

April 18, 2022
BOSTON – Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will host an educational Vision Session at the Rx and Illicit Drug Summit (Rx Summit), April 18-21 in Atlanta, GA. The Rx Summit is the largest annual gathering for global stakeholders to address the opioid and addiction epidemic and share best practices and strategies for prevention, treatment, and recovery.

“The US has seen an unprecedented increase in drug use and overdose deaths during the COVID-19 pandemic, exacerbated by challenges for people living in isolation or with few viable treatment resources available,” said Yuri Maricich, MD, MBA, Chief Medical Officer, Pear Therapeutics. “At this year’s Rx Summit, we look forward to discussing with our clinician panelists how PDTs can address health equity and health care disparities, potentially improve treatment outcomes, and expand access to proven treatment options for people living with addiction.

The Vision Session, titled “Recovery is in Your Hands: How Access to Digital Therapeutics Can Drive Outcomes” will feature a presentation and panel discussion including decision makers who are leading the way to provide access to PDTs. The session will highlight how PDTs for substance use disorder (SUD) and opioid use disorder (OUD) are working to improve access to care for patients, including underserved populations, explore clinical outcomes and real-world engagement data, and discuss how various organizations and key decision makers can pave the way with digital treatments to treat serious diseases.

Panel participants will include:

Shawn Ryan, MD, MBA; President and Chief Medical Officer, BrightView Health
Timothy Aungst, PharmD; Associate Professor at MCPHS University, Worcester, MA, and Clinical Pharmacist in home health care.
Sonji Adams, LPCC, LCADC; Behavioral Health Coordinator, Mountain Comprehensive Health Corporation
George Kitchens, RPh; CEO, Artia Solutions and Former Pharmacy Services Bureau Chief, FL Medicaid
Pear Therapeutics is the category creator and leader in PDTs, having developed the first and only FDA-authorized PDTs to treat SUD and OUD. PDTs are a new therapeutic class that uses software to treat serious disease. Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials to demonstrate safety and effectiveness, evaluated for authorization by regulators like FDA, and used under the supervision of a prescribing clinician. Unlike traditional medicines, PDTs are designed to collect real world data for use by prescribing clinicians and for population health management by payers and health systems.

To learn more about the Session, which will take place on Tuesday, April 19 at 8:00 ET in International Ballroom A-D, please visit www.rx-summit.com/agenda.

For more information on Pear’s PDTs for SUD and OUD, visit www.resetforrecovery.com.

About Pear Therapeutics
Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

reSET Important Safety Information

Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

increase abstinence from a patient’s substances of abuse during treatment, and
increase retention in the outpatient treatment program.
Important Safety Information for Clinicians:

Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

This Press Release does not include all the information needed to use reSET safely and effectively. Please see the Clinician Brief Summary for reSET for more information.

reSET-O Important Safety Information

Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

Important Safety Information for Clinicians:

Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

This Press Release does not include all the information needed to use reSET-O safely and effectively.

Please see the Clinician Brief Summary Instructions for reSET-O for more information.

Filed Under: events

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Agile Software Development Workshop, March 22, 2023
  • GameDev Workshop, From March 10, 2023
  • VPNW 2023, VPN Workshop, March 15, 2023
  • Virtual Job Fair Connects Job Seekers Around the Globe with Employers, February 25, 2023
  • Cloudflare Developer Meetup of 2023, March 16, 2023, Lisbon, Portugal
  • The Electric Vehicles Battery Tech USA Conference is scheduled to take place on March 6-7, 2023 at the Hyatt Regency Orange County
  • The IFA Annual Convention brings together professionals from the franchising industry, February 26 – March 01, 2023, in Las Vegas, NV
  • Tech Summit 2023 explored game-changing technology trends
  • LEX Summit, a legal conference, February 12-15, 2023, at the Hyatt Regency Hotel in Salt Lake City, Utah
  • Essential Considerations for Event Registration and Attendance Management

Media Partners

  • Calendarial
  • Technology Conferences
  • Event Calendar
Blockchain Life Forum 2023, February 27-28, 2023, Dubai
On this day in history, Oct. 21, 1797, legendary warship USS Constitution launched in Boston
Singapore Fintech Festival 2022, November 2-4, 2022, Singapore
Museum Store Sunday, November 27, 2022
The Global IP Europe Exchange, 13-14 March 2023, Berlin
The global State of Open Data Policy Summit takes place on Tuesday, 17 May from 17 CET!
MIT Technology Review’s Future Compute event, April 30 – May 1, 2023, MIT Campus, Cambridge, Massachusetts
Microsoft Research Summit, October 19-21, 2021
DesignCon, the premier event in high-speed communications and system design, August 16-18 2021, San Jose McEnery Convention Center
Web Summit. Europe’s biggest tech conference, November 1-4, 2021, Lisbon
The next New York International Automobile Show takes place August 20 – 29, 2021
Tokyo University of the Arts: Art Fes 2021, until April 30 2021
Gastech to take place in Dubai at the Dubai World Trade Centre from 21-23 September 2021
IAA Mobility 2021, September 7-12, Munich Trade Fair Center, Munich, Germany
CONEXPO-CON/AGG 2023, the largest construction trade show in North America, March 14-18 2023, Las Vegas

Media Partners

  • Technologies.org
  • 3v.org
  • Market Analysis
Tableau Conference, May 9-11, 2023, Las Vegas, NV
Marketing Automation Specialist
MWC Barcelona 2023: 5G technology will surpass 4G by 2029 to become the dominant mobile technology
Canva Launches Brand Management Features and AI-Powered Design Tools to Empower Creatives and Professionals
Why Google executives often choose the wrong problem to solve
Morse Micro Raises $140M in Series B Funding to Accelerate IoT Connectivity and Revolutionize our Digital Future
Retail Media Platform Zitcha Secures $2.9 Million to Enter U.S. Market
Goose Insurance Services, a Vancouver-based insurance technology company, has recently closed a $4 million Series A funding round
Seedtag raises over €250M from Advent International
Blues Wireless Raises $32M To Accelerate Enterprise Adoption of Cellular IoT
China’s economy presents multinational companies with huge risks
The logistics industry is currently undergoing a shift towards increased use of technology and a focus on the Asian market
How Nvidia is set to win big from the hype around ChatGPT
Cisco: Struggling to find new avenues of growth
China’s shrinking population will impede its growth in the future

Copyright © 2022 ESN.net

Media Partners: Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT